Hypercoagulability and thrombotic complications in hemolytic anemias

Haematologica

Volumn 94, Issue 11, 2009, Pages 1481-1484

  Ataga, Kenneth I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; SPHINGOMYELIN; THROMBOPLASTIN; TRANSCRIPTION FACTOR;

BETA THALASSEMIA; EDITORIAL; ENDOTHELIUM CELL; ERYTHROCYTE; HEMOGLOBINOPATHY; HEMOLYTIC ANEMIA; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; MONOCYTE; PATHOPHYSIOLOGY; SICKLE CELL ANEMIA; STROKE; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANEMIA, HEMOLYTIC; ANEMIA, SICKLE CELL; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 70449365408     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013672     Document Type: Editorial

References (39)

1. Ataga KI, Cappellini MD, Rachmilewitz EA. β-thalassemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007;139:3-13. (Pubitemid 47389919)
2. Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 2006; 119:897.e7-11 (Pubitemid 44415626)
3. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96:488-491
4. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M.J. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. Thromb Haemost 2007;5:642-645 (Pubitemid 46680714)
5. Hendrick AM. Auto-immune haemolytic anaemia - a highrisk disorder for thromboembolism. Hematology 2003;8: 53-56 (Pubitemid 36322354)
6. Beutler E, Lang A, Lehmann H. Hemoglobin Duarte: [α2β2 (62) ala leads to pro]: a new unstable hemoglobin with increased oxygen affinity. Blood 1974;43:527-535
7. Au NH, Wong AY, Vickars L, MacGillivray RT, Wadsworth LD. Two new examples of Hb St. Etienne [β92(F8)HisGln] in association with venous thrombosis. Hemoglobin 2009;33:95-100.
8. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36-43.
9. Devaux PF, Zachowski A. Maintenance and consequences of membrane phospholipid asymmetry. Chem Phys Lipids 1994;73:107-120 (Pubitemid 24299191)
10. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-2216
11. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipids asymmetry in blood cells: a review. Blood 1997;89:1121-1132
12. Setty BN, Kulkani S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002;99:1564-1571
13. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001;98:3228-3233
14. Setty BN, Kulkani S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 2000;96:1119-1124
15. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from β-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993;44:63-65 (Pubitemid 23245064)
16. Wandersee NJ, Lee JC, Deveau SA, Barker JE. Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells. Blood 2001;97:3972-3975
17. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683 (Pubitemid 37193612)
18. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Haematologica 2008;93:941-942 (Pubitemid 351821736)
19. Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, et al. Activated platelet-derived microparticles in thalassaemia. Br J Haematol 2007;136:462-471
20. Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2004;125:804-813 (Pubitemid 38813608)
21. Hugel B, Socié G, Vu T, Toti F, Gluckman E, Freyssinet JM, Scrobohaci ML. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999;93:3451-3456 (Pubitemid 29220912)
22. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998;91:4216-4223 (Pubitemid 28261985)
23. Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 2008;6:347-353
24. Solovey A, Kollander R, Shet A, Milbauer LC, Choong S, Panoskaltsis-Mortari A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104:840-846 (Pubitemid 38970583)
25. Lee SP, Ataga KI, Orringer EP, Parise LV. Biologically active CD40 ligand is elevated in sickle cell disease: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc 2006;26:1626-1631
26. Setty BN, ßl SG, Zhang J, Stuart MJ. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008;6:2202-2209
27. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003;9:496-500.
28. Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69
29. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle cell disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110:2166-2172 (Pubitemid 47443936)
30. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-1058 (Pubitemid 17154788)
31. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92:181-187 (Pubitemid 17134934)
32. Gerlach M, Keh D, Bezold G, Spielmann S, Kürer I, Peter RU, et al. Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite. Intensive Care Med 1998;24:1199-1208 (Pubitemid 28542936)
33. Dusse LM, Cooper AJ, Lwaleed BA. Tissue factor and nitric oxide: a controversial relationship! J Thromb Thrombolysis 2007;23:129-133
34. van Beers EJ, Schaap MCL, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF et al. Circulating erythrocytederived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009;94:1513-1519
35. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008;93:20-26 (Pubitemid 351156147)
36. Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasulo MR, Marcon A, Mannucci PM. Hypercoagulability in splenectomized thalassemic patients detected by wholeblood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica 2009;94:xxx-xxx.
37. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001;125:1436-1441 (Pubitemid 33070181)
38. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001;137:398-407.
39. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008;142:126-135 (Pubitemid 351783151)